### FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-028							
Estimated average burden							
haiira nar raananaa.	٥٦						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	d Address of al Christo	Reporting Person <sup>*</sup>							cker or		g Symbol ]				ck all app Dired	ctor	<u> </u>	X 10%	Owner	
(Last) (First) (Middle) C/O FLEX PHARMA, INC. 800 BOYLSTON STREET					3. Date of Earliest Transaction (Month/Day/Year) 10/26/2015								X	X Officer (give title below) Other (specify below)  President and CEO						
(Street) BOSTON (City)	N M.	Α (	)2199 Zip)		- 4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									5. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tabl	e I - N	lon-Deriv	ative	Sec	uritie	s Ac	quire	ed, Di	sposed o	f, or B	enefic	ially	Owne	ed				
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/				Execution Date,				4. Securities Disposed Of			Beneficially Owned Following		ies ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 10/26/20					015	15			P <sup>(1)</sup>		1,043	A	\$10.54	3,91		18,588 D		D		
Common Stock														2,69	97,264		I	By Longwood Fund II. L.P. <sup>(2)</sup>		
		Та	ble II								osed of, convertib				wned					
1. Title of Derivative Security (Instr. 3)	erivative conversion or Exercise (Month/Day/Year) str. 3) Price of Derivative Security  Execution Date, if any (Month/Day/Year)			4. Transa Code ( 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)  Amoun or Numbe of Title Shares		nt er		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y [C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

# **Explanation of Responses:**

## Remarks:

/s/ Robert Hadfield, Attorney-10/28/2015 in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>1. \</sup> The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2015.$ 

<sup>2.</sup> Longwood Fund II GP, LLC is the ultimate General Partner of Longwood Fund II, L.P. Christoph Westphal, M.D., Ph.D., Richard Aldrich and Michelle Dipp, M.D., Ph.D. (collectively, the "Managers") are managers of Longwood Fund II GP, LLC, and, as such, may be deemed to have shared voting and dispositive power with respect to the issuer's securities held by Longwood Fund II, L.P. (the "Longwood Shares"). Each of the Managers disclaims beneficial ownership of the Longwood Shares, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.